Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi ...

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy.

Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced positive topline results from the Phase 1 ...

Amid a flurry of weight loss readouts, a fresh-on-the-scene startup has come out with Phase I results showing weight loss at day 36 on par with or better than competitors, with few gastrointestinal ...

Arch Venture Partners has raised its latest fund of more than $3 billion — its 13th fund to date. The Chicago-based ...

A biotech-focused venture capital firm in Chicago is ready with a new fund as life sciences and biotech continue to find new ...

On the heels of a $3 billion fund from Bain Capital Life Sciences, Arch Venture Partners is proving it can go toe-to-toe with ...

Chicago-based venture-capital firm Arch Venture Partners has closed a new $3 billion fund to invest in early-stage ...

Metsera, the well-funded obesity biotech from Population Health Partners and ARCH Venture Partners, has unveiled its first ...

ARCH Venture Partners is the latest venture capital firm to raise a multi-billion-dollar fund. The cash will be used to ...

Foremost experts in Movement Disorders, which include the fastest-growing brain disease, will convene to share about and guide the direction of global advancements like artificial intelligence.